Sanofi (NASDAQ:SNY) Sees Large Decrease in Short Interest
Sanofi (NASDAQ:SNY – Get Free Report) saw a large decrease in short interest during the month of November. As of November 15th, there was short interest totalling 3,730,000 shares, a decrease of 25.4% from the October 31st total of 5,000,000 shares. Currently, 0.2% of the company’s shares are sold short. Based on an average trading volume of 1,970,000 shares, the days-to-cover ratio is currently 1.9 days.
Analysts Set New Price Targets
Several equities analysts have commented on SNY shares. Stifel Nicolaus downgraded Sanofi from a “buy” rating to a “hold” rating in a research report on Monday, October 30th. StockNews.com started coverage on Sanofi in a report on Thursday, October 5th. They issued a “buy” rating for the company. Finally, Berenberg Bank upgraded Sanofi from a “hold” rating to a “buy” rating in a report on Tuesday, September 5th. One research analyst has rated the stock with a sell rating, one has given a hold rating and seven have issued a buy rating to the company. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $60.00.
Get Our Latest Stock Analysis on SNY
Hedge Funds Weigh In On Sanofi
Several hedge funds and other institutional investors have recently made changes to their positions in the company. Cullen Frost Bankers Inc. lifted its position in shares of Sanofi by 18.2% in the first quarter. Cullen Frost Bankers Inc. now owns 1,182 shares of the company’s stock valued at $64,000 after acquiring an additional 182 shares in the last quarter. Waterfront Wealth Inc. lifted its position in Sanofi by 0.7% during the second quarter. Waterfront Wealth Inc. now owns 27,513 shares of the company’s stock worth $1,482,000 after buying an additional 191 shares in the last quarter. Spire Wealth Management lifted its position in Sanofi by 6.7% during the second quarter. Spire Wealth Management now owns 3,106 shares of the company’s stock worth $167,000 after buying an additional 194 shares in the last quarter. Garrison Asset Management LLC lifted its position in Sanofi by 3.8% during the second quarter. Garrison Asset Management LLC now owns 5,420 shares of the company’s stock worth $288,000 after buying an additional 200 shares in the last quarter. Finally, Oppenheimer & Co. Inc. lifted its position in Sanofi by 2.0% during the second quarter. Oppenheimer & Co. Inc. now owns 10,375 shares of the company’s stock worth $559,000 after buying an additional 200 shares in the last quarter. Hedge funds and other institutional investors own 10.06% of the company’s stock.
Sanofi Stock Performance
Shares of SNY stock traded down $0.03 during mid-day trading on Friday, reaching $46.72. The stock had a trading volume of 1,162,260 shares, compared to its average volume of 1,618,096. The business’s fifty day moving average is $49.67 and its 200-day moving average is $51.77. The company has a current ratio of 1.21, a quick ratio of 0.81 and a debt-to-equity ratio of 0.20. The firm has a market cap of $118.18 billion, a price-to-earnings ratio of 14.65, a PEG ratio of 2.06 and a beta of 0.59. Sanofi has a 1-year low of $42.63 and a 1-year high of $57.82.
Sanofi (NASDAQ:SNY – Get Free Report) last announced its quarterly earnings data on Friday, October 27th. The company reported $1.39 earnings per share for the quarter, beating analysts’ consensus estimates of $1.37 by $0.02. The business had revenue of $13.02 billion for the quarter, compared to analyst estimates of $13.61 billion. Sanofi had a return on equity of 27.55% and a net margin of 17.34%. On average, research analysts forecast that Sanofi will post 4.37 earnings per share for the current year.
About Sanofi (Get Free Report)
Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as dupixent, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.
Further Reading
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat’s editorial team prior to publication. Please send any questions or comments about this story to [email protected].
Before you consider Sanofi, you’ll want to hear this.
MarketBeat keeps track of Wall Street’s top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on… and Sanofi wasn’t on the list.
While Sanofi currently has a “Moderate Buy” rating among analysts, top-rated analysts believe these five stocks are better buys.
Click the link below and we’ll send you MarketBeat’s list of seven best retirement stocks and why they should be in your portfolio.
Original: MarketBeat News Feed: Sanofi (NASDAQ:SNY) Sees Large Decrease in Short Interest